menu
    • menu
    [{"orgOrder":0,"company":"Genesis Therapeutics","sponsor":"Incyte Corporation","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Technology","graph2":"Discovery Platform","graph3":"Genesis Therapeutics","amount2":0.33000000000000002,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0.33000000000000002,"dosageForm":"Undisclosed","sponsorNew":"Genesis Therapeutics \/ Incyte Corporation","highestDevelopmentStatusID":"3","companyTruncated":"Genesis Therapeutics \/ Incyte Corporation"},{"orgOrder":0,"company":"Genesis Therapeutics","sponsor":"Genentech","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Technology","graph2":"Discovery Platform","graph3":"Genesis Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Genesis Therapeutics \/ Genentech","highestDevelopmentStatusID":"3","companyTruncated":"Genesis Therapeutics \/ Genentech"},{"orgOrder":0,"company":"Genesis Therapeutics","sponsor":"Gilead Sciences","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Technology","graph2":"Discovery Platform","graph3":"Genesis Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Genesis Therapeutics \/ Gilead Sciences","highestDevelopmentStatusID":"3","companyTruncated":"Genesis Therapeutics \/ Gilead Sciences"},{"orgOrder":0,"company":"Genesis Therapeutics","sponsor":"Eli Lilly","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Technology","graph2":"Discovery Platform","graph3":"Genesis Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Genesis Therapeutics \/ Eli Lilly","highestDevelopmentStatusID":"3","companyTruncated":"Genesis Therapeutics \/ Eli Lilly"},{"orgOrder":0,"company":"Genesis Therapeutics","sponsor":"Andreessen Horowitz","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Series B Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Technology","graph2":"Discovery Platform","graph3":"Genesis Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Genesis Therapeutics \/ Andreessen Horowitz","highestDevelopmentStatusID":"3","companyTruncated":"Genesis Therapeutics \/ Andreessen Horowitz"}]

    Find Clinical Drug Pipeline Developments & Deals by Genesis Therapeutics

    Menu

    Genesis Therapeutics

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Genesis Therapeutics

                            U.S.A arrow
                            Peptide Therapy Summit
                            Not Confirmed

                            Genesis Therapeutics

                            U.S.A arrow
                            Peptide Therapy Summit
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Technology

                            Study Phase : Discovery Platform

                            Sponsor : Incyte Corporation

                            Deal Size : $325.0 million

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Incyte and Genesis Therapeutics Announce Strategic AI-focused Research Collaboration

                            Details : The collaboration will focus on researching and developing novel small-molecule medicines by leveraging Genesis’ proprietary AI platform, with an initial emphasis on targets selected by Incyte.

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : $30.0 million

                            February 20, 2025

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Technology

                            Highest Development Status : Discovery Platform

                            Sponsor : Incyte Corporation

                            Deal Size : $325.0 million

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Genesis Therapeutics

                            U.S.A arrow
                            Peptide Therapy Summit
                            Not Confirmed

                            Genesis Therapeutics

                            U.S.A arrow
                            Peptide Therapy Summit
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Technology

                            Study Phase : Discovery

                            Sponsor : Gilead Sciences

                            Deal Size : $35.0 million

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Gilead and Genesis Partner To Develop Novel Therapies

                            Details : Gilead Sciences and Genesis Therapeutics entered into a strategic collaboration to discover and develop novel, small molecule therapies across multiple targets.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            October 09, 2024

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Technology

                            Highest Development Status : Discovery

                            Sponsor : Gilead Sciences

                            Deal Size : $35.0 million

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Genesis Therapeutics

                            U.S.A arrow
                            Peptide Therapy Summit
                            Not Confirmed

                            Genesis Therapeutics

                            U.S.A arrow
                            Peptide Therapy Summit
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Technology

                            Study Phase : Discovery Platform

                            Sponsor : Andreessen Horowitz

                            Deal Size : $200.0 million

                            Deal Type : Series B Financing

                            DEALS_DEV arrow-down

                            Genesis Therapeutics Closes Oversubscribed $200 Million Series B

                            Details : The funds will be used to advance Genesis’ pipeline of AI-enabled programs, including its proprietary state-of-the-art generative and predictive AI platform called GEMS (Genesis Exploration of Molecular Space), to accelerate and optimize small molecule...

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            August 21, 2023

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Technology

                            Highest Development Status : Discovery Platform

                            Sponsor : Andreessen Horowitz

                            Deal Size : $200.0 million

                            Deal Type : Series B Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Genesis Therapeutics

                            U.S.A arrow
                            Peptide Therapy Summit
                            Not Confirmed

                            Genesis Therapeutics

                            U.S.A arrow
                            Peptide Therapy Summit
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Technology

                            Study Phase : Discovery Platform

                            Sponsor : Eli Lilly

                            Deal Size : $670.0 million

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Genesis Therapeutics Announces Strategic Collaboration with Lilly to Discover Novel Therapies Using the Genesi...

                            Details : The collaboration will deploy Genesis’ pioneering AI drug discovery platform, which combines 3D structure-aware deep neural networks with cutting-edge molecular simulation.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : $20.0 million

                            March 05, 2022

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Technology

                            Highest Development Status : Discovery Platform

                            Sponsor : Eli Lilly

                            Deal Size : $670.0 million

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Genesis Therapeutics

                            U.S.A arrow
                            Peptide Therapy Summit
                            Not Confirmed

                            Genesis Therapeutics

                            U.S.A arrow
                            Peptide Therapy Summit
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Technology

                            Study Phase : Discovery Platform

                            Sponsor : Genentech

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Genesis, Genentech Form AI-Driven Multi-Target Drug Discovery Collaboration

                            Details : Through the partnership, Genentech will leverages Genesis’ graph machine learning and drug discovery expertise to identify innovative drug candidates for therapeutic targets in multiple disease areas.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            October 19, 2020

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Technology

                            Highest Development Status : Discovery Platform

                            Sponsor : Genentech

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth